CPR Therapeutics Inc. (CPR-T), a Vermont-based medical device start-up company, announced today that it has received three U.S. patents for inventions that will contribute to the development of its breakthrough technology for cardiopulmonary resuscitation.
The first patent (US11,684,542) is for CPR devices that use more than one type of compression pattern to increase blood flow on both sides of the heart.
The second (US11,679,059) is for CPR devices that push on the patient’s chest in varying locations and in differing combinations as a means to provide precision personalized resuscitation and enhance blood flow.
The third, (US11,684,541) is for circumferential vest CPR devices that enhance blood return to the heart as a means of increasing overall blood flow. This patent was simultaneously allowed by the European Patent Office.
Funded by both the National Institutes of Health and the National Science Foundation, CPR Therapeutics Inc. is developing the first advanced technology automated CPR system that integrates and synchronizes multiple innovations into a single system that can be easily applied under emergency conditions. This multimodal CPR cannot be performed by humans, and significantly increases blood flow to the heart and brain while enhancing electrical countershock in ways previously only available in laboratory settings. Increased blood flow and more effective countershock will both contribute to better patient outcomes in cardiac arrest, the leading single killer in Western Countries.
Norman Paradis MD, CPR Therapeutics Founder and CEO stated: “Receiving all three patents in one week is a wonderful coincidence that highlights the breadth of our innovation. We already knew that our existing patent portfolio was strong and provided a sound foundation for our future commercial efforts. Now it is even stronger. I believe any one of these patents could justifiably be called a breakthrough invention in and of itself.”
Nathaniel A. Wickliffe, the company’s patent attorney commented: ”It is always pleasing when the originality and utility of a client’s invention is validated by the U.S. Patent Office. Each of these patents individually would be a source of pride for an early-stage medical device startup. Taken together, and added to the company’s already deep and broad intellectual property portfolio, they contribute to CPR
Therapeutics’ strong intellectual property position.”
Lastly, Dr. Paradis added: “These are major milestones for the company and add to our first-mover advantage with respect to next generation CPR. It would be hard to overestimate the head-start we have in developing the first broadly innovative, widely applicable, and clinically effective treatment for this major unmet medical need.”
